Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
A combination therapy consisting of azacitidine, a hypomethylating agent that works by blocking enzymes needed for cell growth and can induce expression of multiple genes including cancer-testis antigens. Pembrolizumab is a humanized monoclonal antibody targeting PD-1 (programmed cell death protein 1), blocking its interaction with ligands PD-L1 and PD-L2. This combination aims to enhance antitumor immune responses, as hypomethylating agents can increase expression of immune checkpoints, and anti-PD-1 antibodies can block the interaction between PD-1 and its ligands PD-L1 and PD-L2.
- Brand names
- KeytrudaVidaza
- Other names
- Azacytidine and Pembrolizumab
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on azacitidine + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + pembrolizumab.